DEBBIE ZAMORA: Open Payments
NPI 1326389974 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$962 in 16 payments from 9 companies in 2025. Trend: 2023 $797 · 2024 $724 · 2025 $962
Food & beverage: $872Education: $90
| Company | Payments | Amount |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | 2 | $254 |
| Iovance Biotherapeutics, Inc. | 2 | $189 |
| JAZZ PHARMACEUTICALS INC. | 1 | $140 |
| ABBVIE INC. | 3 | $130 |
| BeOne Medicines USA, Inc. | 3 | $76 |
| Melinta Therapeutics, LLC | 2 | $66 |
| E.R. Squibb & Sons, L.L.C. | 1 | $62 |
| Janssen Biotech, Inc. | 1 | $30 |
| Genentech USA, Inc. | 1 | $15 |
Products named: Amtagvi, DEFITELIO, IMBRUVICA, BRUKINSA, Rezzayo, BREYANZI, Venclexta, TALVEY.
Industry payments across CA — which companies pay providers there.
